Survol des décisions et des modifications législatives significatives en matières de brevets pharmaceutiques en 2017
Bibliographic record
Abstract
L’encadrement juridique de la validite des brevets, portant sur les medicaments, permet la recherche d’un equilibre entre les compagnies « innovatrices » et « generiques », ce qui se traduit habituellement en un acces a des medicaments novateurs et une baisse des prix au profit des consommateurs. Le present article se veut une selection editoriale de quatre decisions d’interet en matiere de brevets pharmaceutiques rendues au cours de l’annee 2017. Ces decisions ont, entre autres, permis de clarifier les criteres de validite des brevets relatifs a l’utilite, la suffisance de la description et l’activite inventive et de mieux definir les pouvoirs du Conseil d’examen du prix des medicaments brevetes. L’article resume les changements legislatifs effectues par le Canada, afi n de remplir ses obligations au terme de la conclusion de l’Accord economique et commercial global (AECG) entre le Canada et l’Union europeenne, ainsi que les effets des nouvelles dispositions sur la mise en marche et la protection par brevets des produits pharmaceutiques au Canada. The legal framework for the validity of patents concerning medicines, allows the search for a balance between « innovative » and « generic » companies, which usually results in access to innovative medicines and lower prices for the benefit of consumers. This article aims to be an editorial selection of four decisions of interest regarding pharmaceutical potents rendered in 2017. These decisions allowed, among others, to clarify the criteria of validity of patents relating to utility, adequacy of the description and inventive step and to better define the powers of the Patented Medicine Prices Review Board. The article summarizes the legislative changes made by Canada to fulfill its obligations following the conclusion of the Canada-European Comprehensive Economic and Trade Agreement, as well as the effects of the new provisions on the marketing and protection by patents of pharmaceutical products in Canada.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.022 | 0.046 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.003 | 0.004 |
| Science and technology studies | 0.013 | 0.007 |
| Scholarly communication | 0.015 | 0.003 |
| Open science | 0.003 | 0.004 |
| Research integrity | 0.010 | 0.009 |
| Insufficient payload (model declined to judge) | 0.011 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".